Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 439, 274-275 (19 January 2006) | doi:10.1038/439274a; Published online 18 January 2006
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Novel Approaches to Protecting Maize from Insect Damage
The Seeker is looking for novel approaches to protecting maize from insect damage. This Challenge re...
- More Challenges
- Powered by:
nature jobs
Manager / Sr. Manager - Business Development (Custom Synthesis)
- Syngene International
- Bangalore, Karnataka 560099 India
Metabolomics Scientist in Nutrition
- Nestle Research Center
- Lausanne Switzerland
Cancer biology: Signatures guide drug choice
Julian Downward1
Abstract
Cancer drugs are increasingly designed to target specific cell-signalling pathways. When, and in what combination, these drugs should be used might be judged by analysing the gene expression signature of the tumour.
Current approaches to the design of drugs against cancer assume that almost all tumours escape normal growth regulation by usurping a few of the dozen or so key cell-signalling pathways. However, pathways can be activated at different points, so it is not always easy to tell which signalling mechanism has been activated by looking for mutations in known cancer-associated genes (oncogenes, or tumour-suppressor genes).
- Julian Downward is at the Cancer Research UK London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3PX, UK.
Email: downward@cancer.org.uk
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Targeting RAS and PI3K in lung cancerNature Medicine News and Views (01 Dec 2008)
Cancer Crime and punishmentNature News and Views (04 Aug 2005)
RESEARCH
Evidence that bone morphogenetic protein 4 has multiple biological functions during kidney and urinary tract developmentKidney International Original Article
Mutually exclusive NRAS Q61R and BRAF V600E mutations at the single-cell level in the same human melanomaOncogene Original Article
See all 21 matches for Research